Esperance
Pharmaceuticals introduced the finishing of the run-in cohort of its Phase 2,
randomized, multicenter trial of EP-100 in
conjunction with paclitaxel for affected individuals with superior ovarian
cancer. EP-100 is a specified membrane-disrupting peptide devised to seek and
destroy cancer receptors which typically over express luteinizing hormone
releasing hormones (LHRH)
receptors upon their surfaces.
LHRH
receptors are over expressed in a wide variety of cancers such as ovarian
cancer. In June, the firm presented achievements from the successful finishing
of a Phase 1 research study of EP-100 in advanced solid tumors at the American
Society of Clinical Oncology (ASCO) Annual Meeting.
"We are satisfied with the
sustained momentum following EP-100 and the progress of joining as we start the
randomized therapy phase,"
said Dr. Hector Alila, CEO of Esperance. "We are provoked with early
achievements, and look forward to boosting enrollment in an extremely
important, underserved affected individual’s population and offering an update
on the clinical improvement eventually."
No comments:
Post a Comment